ICU Medical Inc
NASDAQ:ICUI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
84.39
183.83
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ICU Medical Inc
Gross Profit
ICU Medical Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
ICU Medical Inc
NASDAQ:ICUI
|
Gross Profit
$769.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
||
Haemonetics Corp
NYSE:HAE
|
Gross Profit
$735.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
||
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Gross Profit
$2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
||
Align Technology Inc
NASDAQ:ALGN
|
Gross Profit
$2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
Gross Profit
$969.6m
|
CAGR 3-Years
78%
|
CAGR 5-Years
41%
|
CAGR 10-Years
25%
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
Gross Profit
$620.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
ICU Medical Inc
Glance View
ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 8,500 full-time employees. The firm provides infusion systems, infusion consumables and critical care products used in hospital, alternate site and home care settings. The firm's product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle free connectors. Its oncology products include ChemoLock and ChemoClave. Its IV consumables include Clave IV Connector Technology, IV Sets, Peripheral IV Catheters and Disinfecting Caps. Its primary critical care products include Cogent, CardioFlo, TDQ and OptiQ, TriOx, Transpac and SafeSet. Its IV Solutions products include IV Therapy and Diluents, and Irrigation. Its Infusion System products include Infusion Pump Hardware, IV Mediation Safety Software and Professional Services. The company offers blood pressure monitoring system.
See Also
What is ICU Medical Inc's Gross Profit?
Gross Profit
769.1m
USD
Based on the financial report for Sep 30, 2024, ICU Medical Inc's Gross Profit amounts to 769.1m USD.
What is ICU Medical Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
18%
Over the last year, the Gross Profit growth was 4%. The average annual Gross Profit growth rates for ICU Medical Inc have been 17% over the past three years , 9% over the past five years , and 18% over the past ten years .